



Duncan Barbara Gayle - SEC Form 4 Insider Trading Screener - OpenInsider











OpenInsider

Latest

Latest Cluster Buys
Latest Insider Trading (all filings)
Latest Insider Purchases
Latest Insider Purchases $25k+
Latest Officer Purchases $25k+
Latest CEO/CFO Purchases $25k+
Latest Insider Sales
Latest Insider Sales $100k+
Latest Officer Sales $100k+
Latest CEO/CFO Sales $100k+


Top

Top Officer Purchases Today
Top Officer Purchases Past Week
Top Officer Purchases Past Month
Top Insider Purchases Today
Top Insider Purchases Past Week
Top Insider Purchases Past Month
Top Insider Sales Today
Top Insider Sales Past Week
Top Insider Sales Past Month


By Symbol

Officer Purchases $25k+ Today
Officer Purchases $25k+ Past Week
Officer Purchases $25k+ Past Month
Officer Sales $100k+ Today
Officer Sales $200k+ Past Week
Officer Sales $500k+ Past Month
Officer Sales $100k+ Today (no opt-ex)
Officer Sales $200k+ Past Week (no opt-ex)
Officer Sales $500k+ Past Month (no opt-ex)
Insider Purchases of Penny Stocks, Past Month
Insider Sales of Penny Stocks, Past Month


Charts

Contact











Duncan Barbara Gayle - SEC Form 4 Insider Trading ScreenerCIK: 1353128 - Address: 2000 Sierra Point Parkway, Suite 500, Brisbane, CA 94005 




General

Tickers
Insider
Sh Price $



Lqdty M$






Date

Filing Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  



Trade Date

All dates
Custom
Latest day
Last 3 days
Last 1 week
Last 2 weeks
Last 1 month
Last 2 months
Last 3 months
Last 6 months
Last 1 year
Last 2 years
Last 4 years



  


Filing Delay



N Days Ago








Transaction Filing

 P - Purchase S - Sale A - Grant D - Sale to Iss G - Gift F - Tax M - Option Ex X - Option Ex C - Cnv Deriv W - Inherited

 No deriv


 Multiple Days

Traded K$



Own Chg %








Industry




All Sectors (except Funds)
Agriculture, Forestry, Fish
Mining
Construction
Manufacturing
Transportation & Utilities
Wholesale Trade
Retail Trade
Financial
Services
Closed-End Funds


























Insider Title

  Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other






Group by


Filing
Company





Company Totals

Num Filings



Num Insiders



Num Officers



Traded K$



Own Chg %







Sort by

Filing Date
Trade Date
Ticker Symbol
Trade Value


Max Results
Page


clear


Real-time CSV, Options, Alerts








5 results -  -  -  -  -  -  - TCcnt1d1w1m6mS5-1-5-13-14 


X
Filing Date
Trade Date
Ticker
Insider NameInsider Title
Trade Type 
Share Price
Shares Traded
Shares Owned
Own chg
Value Traded
1d ret
1w ret
1m ret
6m ret



2016-10-05 21:04:412016-10-03 ICPTDuncan Barbara GayleChief Accounting OfficerS - Sale$163.20-14730,6610%-$23,9900-1-24-29
2016-07-07 21:03:232016-07-05 ICPTDuncan Barbara GayleChief Accounting OfficerS - Sale$145.11-14630,8080%-$21,186+6+1+14-25
2016-04-06 21:00:262016-04-04 ICPTDuncan Barbara GayleCFOS - Sale$130.76-14430,9480%-$18,8290-11-16-1
D2016-01-05 21:00:502016-01-04 ICPTDuncan Barbara GayleCFOS - Sale+OE$145.90-46824,892-2%-$68,283-8-19-36-5
DM2015-10-05 21:02:362015-10-01 ICPTDuncan Barbara GayleCFOS - Sale+OE$163.17-1,05424,062-4%-$171,978-4+5-2-12
Real-time CSV? Options? Alerts? Contact us!



AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price


S - SaleSale of securities on an exchange or to another personS - Sale+OESale of securities on an exchange or to another person (after option exercise)F - TaxPayment of exercise price or tax liability using portion of securities received from the companyP - PurchasePurchase of securities on an exchange or from another person 

Return to top
Copyright © 2017 openinsider.com. All rights reserved.












    Barbara Duncan | Adaptimmune Therapeutics PLC | ZoomInfo.com



Insider trading history of Duncan Barbara Gayle    at Intercept Pharmaceuticals Inc 



















Insider Monitor



Realtime

Insider Buys 

Insider buys today     
Insider buys 1 day ago
Insider buys 2 days ago
Insider buys 3 days ago
Insider buys 4 days ago
Insider buys 5 days ago
Insider buys 6 days ago
Insider buys 7 days ago
Insider buys 8 days ago
Insider buys 9 days ago
Insider buys 10 days ago



Insider Sales 

Insider sales today       
Insider sales 1 day ago
Insider sales 2 days ago
Insider sales 3 days ago
Insider sales 4 days ago
Insider sales 5 days ago
Insider sales 6 days ago
Insider sales 7 days ago



Top 10 

Top 10 insider buys of the week
Top 10 officer buys of the week
Top 10 insider buys of the month
Top 10 officer buys of the month
Top 10 insider sales of the week
Top 10 insider sales of the month









               
		







 Insider Stock Trading History of Duncan Barbara Gayle  








The following table details the trading activities 
(stock purchases, stock sales, and stock option exercises) 
reported to 
the Securities and Exchange Commission (SEC) 
by insider Duncan Barbara Gayle  since year 2005. 
The trader's CIK number is 1353128.
At the time of this reporting, Duncan Barbara Gayle  is the Chief Accounting Officer of Intercept Pharmaceuticals Inc . 
(stock ticker symbol ICPT).
See this page for all insider trading activities at Intercept Pharmaceuticals Inc . 





Stock purchases, sales, and option exercises reported by insider Duncan Barbara Gayle  since 2005.
  

   Trade Date   
 Symbol 
 Company Name (Issuer) 
 Trade Type 
     Shares   
     Price ($)
   Value ($) 

 2016-10-03  ICPT  Intercept Pharmaceuticals Inc   Sale  147  163.20  23,990 
 2016-07-05  ICPT  Intercept Pharmaceuticals Inc   Sale  146  145.11  21,185 
 2016-04-04  ICPT  Intercept Pharmaceuticals Inc   Sale  144  130.76  18,829 
 2016-01-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2016-01-04  ICPT  Intercept Pharmaceuticals Inc   Sale  468  145.90  68,283 
 2015-10-02  ICPT  Intercept Pharmaceuticals Inc   Sale  54  159.04  8,588 
 2015-10-01  ICPT  Intercept Pharmaceuticals Inc   Sale  1,000  163.39  163,390 
 2015-10-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  2,298  4.33  9,957 
 2015-07-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2015-07-02  ICPT  Intercept Pharmaceuticals Inc   Sale  53  237.76  12,601 
 2015-07-01  ICPT  Intercept Pharmaceuticals Inc   Sale  1,000  242.10  242,100 
 2015-07-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,000  8.67  8,667 
 2015-04-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2015-04-02  ICPT  Intercept Pharmaceuticals Inc   Sale  39  277.70  10,830 
 2015-03-27  ICPT  Intercept Pharmaceuticals Inc   Sale  1,000  288.94  288,937 
 2015-01-05  ICPT  Intercept Pharmaceuticals Inc   Sale  141  176.49  24,884 
 2015-01-02  ICPT  Intercept Pharmaceuticals Inc   Sale  1,000  156.40  156,400 
 2015-01-02  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,000  31.90  31,900 
 2015-01-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2014-10-01  ICPT  Intercept Pharmaceuticals Inc   Sale  1,000  233.90  233,897 
 2014-10-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  2,299  15.95  36,669 
 2014-07-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2014-04-14  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,154  21.50  24,811 
 2014-04-14  ICPT  Intercept Pharmaceuticals Inc   Sale  1,154  279.00  321,966 
 2014-04-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2014-01-15  ICPT  Intercept Pharmaceuticals Inc   Sale  5,625  263.12  1,480,038 
 2014-01-15  ICPT  Intercept Pharmaceuticals Inc   Option Ex  5,625  31.90  179,437 
 2014-01-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2013-10-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2013-07-08  ICPT  Intercept Pharmaceuticals Inc   Option Ex  25,000  9.82  245,549 
 2013-07-08  ICPT  Intercept Pharmaceuticals Inc   Sale  25,000  45.39  1,134,850 
 2013-07-01  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,298  .00  0 
 2013-06-19  ICPT  Intercept Pharmaceuticals Inc   Sale  50,575  34.50  1,744,837 
 2013-06-19  ICPT  Intercept Pharmaceuticals Inc   Option Ex  50,575  9.24  467,565 
 2013-05-23  ICPT  Intercept Pharmaceuticals Inc   Sale  110  34.54  3,799 
 2013-05-24  ICPT  Intercept Pharmaceuticals Inc   Option Ex  1,200  8.67  10,400 
 2013-05-23  ICPT  Intercept Pharmaceuticals Inc   Option Ex  110  8.67  953 
 2013-05-28  ICPT  Intercept Pharmaceuticals Inc   Sale  4,915  34.50  169,567 
 2013-05-28  ICPT  Intercept Pharmaceuticals Inc   Option Ex  4,915  8.67  42,598 
 2013-05-24  ICPT  Intercept Pharmaceuticals Inc   Sale  1,200  34.50  41,400 
 2013-05-20  ICPT  Intercept Pharmaceuticals Inc   Option Ex  28,200  15.08  425,340 
 2013-05-20  ICPT  Intercept Pharmaceuticals Inc   Sale  28,200  34.50  972,900 
 2013-04-09  ICPT  Intercept Pharmaceuticals Inc   Option Ex  6,490  .00  0 


Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more  information regarding the trades made by Duncan Barbara Gayle  
(Chief Accounting Officer of Intercept Pharmaceuticals Inc  at the time of this reporting) see 

the Securities and Exchange Commission (SEC)  website.


















 



















Newest Insider Buys 
Insider Trading Resources 
Archive  
Privacy  
Contact  
2016,2017 Market Holidays 
Market Hours 






Tweet



 ©2017, insider-monitor.com. All rights reserved. 
 
















Barbara Gayle Duncan - Woodbridge, NJ | Intelius



























Sign In



We found Barbara Gayle Duncan in Woodbridge, NJ


Barbara Gayle Duncan

                                                                                       Intelius found that Barbara Gayle Duncan  is  a female between 60 and 70 years old from Woodbridge, NJ.  We have connected them to
                16 addresses,
                9 phones,
                and 4 relatives or associates.
         






Get Report Now

Age

Barbara Gayle Duncan is in her 60s

Barbara Has Lived In

Woodbridge, NJ
Montclair, NJ
West Orange, NJ

Barbara's Relatives

Erica Duncan
Albert Duncan
Angela Duncan
Stephanie Duncan







Barbara Gayle Duncan



Zodiac SignTaurus



GenderFemale



Professional Status
Board Member at Medgenics Inc



Get Report Now










Want to know more about Barbara? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Barbara, or use our people search engine to find others.
Get Background Check on Barbara Gayle Duncan
Get a Criminal Check on Barbara Gayle Duncan
Get a Public Record Report on Barbara Gayle Duncan
Get a People Search Report on Barbara Gayle Duncan


Barbara Gayle Duncan's Contact Information
Known Cities Lived In
Find out where Barbara Gayle Duncan has lived as well as Barbara Gayle Duncan's phone numbers and email addresses.




Barbara Gayle Duncan Has Lived in 3 States
New Jersey Address for Barbara Gayle Duncan


311 M*** S* 

Woodbridge, NJ


Has Lived In

Woodbridge, NJ
Montclair, NJ


Get Full Address Report










Phone Numbers Associated with Barbara Gayle Duncan

(732) ***-**** - Woodbridge, NJ 
(732) ***-**** - Woodbridge, NJ 
(201) ***-**** - Fort Lee, NJ 


Get Full Phone Report



Email Addresses Associated with Barbara Gayle Duncan

b****1@***.net
b****1@***.com
b****1@***.com


Get Email Report




Barbara Gayle Duncan's Education Information
Known Schools Attended
Learn about Barbara Gayle Duncan's academic history.  Find out which schools Barbara Gayle Duncan attended, the dates attended as well as the degrees Barbara Gayle Duncan received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Barbara Gayle Duncan Has Attended 1 School
 


Barbara Gayle Duncan's Professional Information
Information regarding Barbara Gayle Duncan's professional history.  Find out previous places Barbara Gayle Duncan has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Barbara Gayle Duncan Has Worked at 1 Place
Company: Medgenics Inc
               Title: Board Member
Barbara Gayle Duncan's Experience
Title: Board Member
               Company: Medgenics Inc
Job Details
               Medgenics, Inc. (Medgenics) is a holding company with one wholly owned subsidiary Medgenics Medical Israel Ltd. The Company and its subsidiary are engaged in the research and development of products in the field of biotechnology and associated medical equipment. The Company is considered as a development-stage company. It is developing a platform technology- a biological Biopump, which allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C. Medgenics is focused on developing its Biopump platform for anemia (EPODURE, producing erythropoietin (EPO)) and hepatitis C (INFRADURE, which produces interferon-alpha (IFN-a)). In addition, the Company’s platform technology has the potential to treat a range of other therapeutic areas, such as diabetes, arthritis, wound healing, obesity, chronic pain and cancer recovery.
Additional Professional Information on Barbara Gayle Duncan

 See Barbara Gayle Duncan's LinkedIn Profile



Barbara Gayle Duncan's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Barbara Gayle Duncan


Barbara Gayle Duncan's known Social Networks And Potential Email Matches

Find all of Barbara Gayle Duncan's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Barbara Duncan
Username Matches

                  BarbaraDuncan
                  DuncanBarbara
                  Barbara.Duncan
                  Duncan.Barbara
                  Barbara_Duncan
                  Duncan_Barbara
                  Barbara-Duncan
                  Duncan-Barbara
                  BDuncan
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
B Duncan







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.














ICPT Barbara Gayle Duncan Insider Trades for Intercept Pharmaceuticals Inc.


































X

Tweet
 

Share this bulletin

Get news bulletins by email

Bulletin

Amazon tagged with 3.5% loss early Friday, pacing consumer-discretionary skid »
        




Investor Alert







New York Markets Close in:



Market Snapshot
Winners and Losers


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Intercept Pharmaceuticals Inc.

                  NASDAQ: ICPT
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Intercept Pharmaceuticals Inc.



Market open
 --Real time quotes
Jul 28, 2017, 10:05 a.m.


ICPT

/quotes/zigman/12230574/composite


$
128.59




Change

-0.97
-0.75%

Volume
Volume 46,794
Real time quotes








/quotes/zigman/12230574/composite
Previous close

$
			129.56
		


$
				128.59
			
Change

-0.97
-0.75%





Day low
Day high
$128.18
$130.67










52 week low
52 week high

            $96.63
        

            $177.93
        


















Insider Activity


Individual




Barbara Gayle Duncan



Ms. Barbara G. Duncan is Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc. She is on the Board of Directors at Medgenics, Inc. and Edgemont Pharmaceuticals LLC.
Ms. Duncan was previously employed as Chief Executive & Financial Officer by DOV Pharmaceutical, Inc., Vice President-Corporate Finance Division by Lehman Brothers, Inc., a Director & Associate by SBC Warburg Dillon Read Corporate Finance AG, a Principal by PepsiCo, Inc., and a Principal by D&T Partners LLP.
She received her undergraduate degree from Louisiana State University and an MBA from The Wharton School of the University of Pennsylvania.



Transactions


Date
Shares
Transaction
Value





10/03/2016
147


 
Disposition at $163.2 per share.


23,991


07/05/2016
146


 
Disposition at $145.11 per share.


21,187


04/04/2016
144


 
Disposition at $130.76 per share.


18,830


02/10/2016
6,200


 
Award at $0 per share.


0


01/04/2016
428


 
Disposition at $145.9 per share.


62,446


01/04/2016
40


 
Disposition at $145.9 per share.


5,836


01/01/2016
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


10/02/2015
54


 
Disposition at $159.04 per share.


8,589


10/01/2015
1,000


 
Disposition at $163.39 per share.


163,390


10/01/2015
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


10/01/2015
1,000


 
Derivative/Non-derivative trans. at $8.67 per share.


8,670


10/01/2015
4,050


 
Award at $0 per share.


0


07/02/2015
1


 
Disposition at $239 per share.


239


07/02/2015
2


 
Disposition at $238.16 per share.


477


07/02/2015
50


 
Disposition at $236.13 per share.


11,807


07/01/2015
1,000


 
Disposition at $242.1 per share.


242,100


07/01/2015
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


07/01/2015
1,000


 
Derivative/Non-derivative trans. at $8.67 per share.


8,670


04/02/2015
39


 
Disposition at $277.7 per share.


10,831


04/01/2015
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


03/27/2015
300


 
Disposition at $293.34 per share.


88,002


03/27/2015
100


 
Disposition at $292.16 per share.


29,216


03/27/2015
100


 
Disposition at $291 per share.


29,100


03/27/2015
100


 
Disposition at $289 per share.


28,900


03/27/2015
100


 
Disposition at $288 per share.


28,800


03/27/2015
100


 
Disposition at $287 per share.


28,700


03/27/2015
100


 
Disposition at $286 per share.


28,600


03/27/2015
100


 
Disposition at $285 per share.


28,500


01/05/2015
141


 
Disposition at $176.49 per share.


24,886


01/02/2015
500


 
Disposition at $158.35 per share.


79,175


01/02/2015
500


 
Disposition at $154.45 per share.


77,225


01/02/2015
1,000


 
Derivative/Non-derivative trans. at $31.9 per share.


31,900


01/01/2015
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


10/01/2014
100


 
Disposition at $234.87 per share.


23,487


10/01/2014
900


 
Disposition at $232.92 per share.


209,628


10/01/2014
1,000


 
Derivative/Non-derivative trans. at $31.9 per share.


31,900


10/01/2014
1,299


 
Derivative/Non-derivative trans. at $0 per share.


0


07/01/2014
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


04/14/2014
1,154


 
Disposition at $279 per share.


321,966


04/14/2014
1,154


 
Derivative/Non-derivative trans. at $21.5 per share.


24,811


04/11/2014
1,504


 
Award at $0 per share.


0


04/01/2014
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2014
250


 
Disposition at $262 per share.


65,500


01/15/2014
500


 
Disposition at $260 per share.


130,000


01/15/2014
500


 
Disposition at $258.3 per share.


129,150


01/15/2014
750


 
Disposition at $257.27 per share.


192,953


01/15/2014
500


 
Disposition at $256 per share.


128,000


01/15/2014
500


 
Disposition at $255 per share.


127,500


01/15/2014
1,150


 
Disposition at $253.63 per share.


291,675


01/15/2014
300


 
Disposition at $251.55 per share.


75,465


01/15/2014
250


 
Disposition at $283.9 per share.


70,975


01/15/2014
125


 
Disposition at $280 per share.


35,000


01/15/2014
50


 
Disposition at $274 per share.


13,700


01/15/2014
250


 
Disposition at $265 per share.


66,250


01/15/2014
250


 
Disposition at $264 per share.


66,000


01/15/2014
250


 
Disposition at $263 per share.


65,750


01/15/2014
5,625


 
Derivative/Non-derivative trans. at $31.9 per share.


179,437


01/01/2014
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


10/01/2013
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


07/08/2013
25,000


 
Disposition at $45.39 per share.


1,134,750


07/08/2013
25,000


 
Derivative/Non-derivative trans. at $9.82 per share.


245,500


07/01/2013
1,298


 
Derivative/Non-derivative trans. at $0 per share.


0


06/19/2013
50,575


 
Disposition at $34.5 per share.


1,744,838


06/19/2013
42,018


 
Derivative/Non-derivative trans. at $9.82 per share.


412,616


06/19/2013
8,557


 
Derivative/Non-derivative trans. at $8.67 per share.


74,189


05/28/2013
4,915


 
Disposition at $34.5 per share.


169,568


05/28/2013
4,915


 
Derivative/Non-derivative trans. at $8.67 per share.


42,613


05/24/2013
1,200


 
Disposition at $34.5 per share.


41,400


05/24/2013
1,200


 
Derivative/Non-derivative trans. at $8.67 per share.


10,404


05/23/2013
110


 
Disposition at $34.54 per share.


3,800


05/23/2013
110


 
Derivative/Non-derivative trans. at $8.67 per share.


953


05/20/2013
100


 
Disposition at $34.5 per share.


3,450


05/20/2013
100


 
Disposition at $34.5 per share.


3,450


05/20/2013
28,000


 
Disposition at $34.5 per share.


966,000


05/20/2013
23,873


 
Derivative/Non-derivative trans. at $8.67 per share.


206,978


05/20/2013
4,327


 
Derivative/Non-derivative trans. at $21.5 per share.


93,030


05/07/2013
3,000


 
Award at $0 per share.


0


04/09/2013
2,676


 
Derivative/Non-derivative trans. at $34.57 per share.


92,510


04/09/2013
6,490


 
Derivative/Non-derivative trans. at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Mark E. Pruzanski 
President, Chief Executive Officer & Director




Mr. Jerome B. Durso 
Chief Operating Officer




Mr. Sandip S. Kapadia 
Chief Financial Officer




Dr. David A. Shapiro 
Chief Medical Officer & Executive VP-Development




Mr. Richard  Kim 
Senior Vice President-Commercial Head of US




Dr. Juan Carlos  Lopez-Talavera 
Senior Vice President-Head Medical Affairs




Ms. Lisa  Bright 
President-International




Dr. Rachel L. McMinn 
Chief Business & Strategy Officer




Mr. Christopher  Frates 
Media Contact




Dr. Mark J. Vignola 
Director-Investor Relations




Mr. Paolo  Fundarò 
Chairman




Dr. Keith M. Gottesdiener 
Independent Director




Mr. Daniel Mark Bradbury 
Independent Director




Mr. Daniel G. Welch 
Independent Director




Mr. Gino  Santini 
Independent Director




Dr. Luca  Benatti 
Independent Director




Mr. Glenn P. Sblendorio 
Independent Director




Dr. Srinivas  Akkaraju 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




10:05 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Open


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
10:05aMinor lift for final consumer sentiment reading in July as partisan divide remains
10:03aU.S. dollar holds decline after consumer sentiment data
10:03aTreasury yields flat after consumer sentiment data 
10:01aFinal UMich consumer sentiment for July was 93.4
10:00aBojangles' shares sink after revenue miss, guidance cut
10:00aTreasury to wind down the myRA retirement savings program
9:58aCan Christopher Nolan’s ‘Dunkirk’ crack China’s market? 
9:55aThis type of investing could save the world — just don’t expect outperformance, too
9:54aThese tips can help advisers attract — and keep — high net worth clients
9:54aA menacing pattern has revealed itself in the stock market
9:53aTeaching people how to invest is one of the best marketing moves an adviser can make
9:45aA case for buying the freakin’ dip with Amazon, as the Mooch might now say
9:43aConsumer-discretionary sector slides as Amazon shares drop on results
9:42aShares of newspaper publisher McClatchy are up more than 2%
9:42a5 cities where you can buy a HUGE house for $100,000 or less
9:42aHow advisers can fight the ‘crisis of trust’ in financial services
9:38aBREAKINGStock market opens lower as Wall Street resumes tech selling
9:38aDestination Maternity plummets toward record low after merger deal terminated
9:38aThis is how Congress could craft a bipartisan health-care bill
9:36aMeet the ‘Hamilton’ actors who fly cross-country and play up to 18 roles in the hit show
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,769.38

-27.17
-0.12%





nasdaq

/quotes/zigman/12633936/realtime
6,361.26

-20.93
-0.33%





s&p 500

/quotes/zigman/3870025/realtime
2,468.74

-6.68
-0.27%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft

















Barbara Gayle Duncan - Director Information (UK)















UK Corporate Information













COMPANIES
DIRECTORS












HomeCompany SearchDirector Search












HomeCompany SearchDirector SearchCompany by Zip Code










Barbara Gayle Duncan
Glass Wharf, , Bristol, , BS2 0ZX


OVERVIEW - Barbara Gayle DuncanLATEST NEWS









Barbara Gayle Duncan



Barbara Gayle Duncan was Born in December, 1964 (53 years old)  a resident of Glass Wharf, , Bristol, , BS2 0ZX (Usa) having American nationality and was first ever appointed as Director in Intercept Pharma Europe Limited on Thursday 18 September 2014 and as per the records from Registrar of Companies last appointment was in Adaptimmune Therapeutics Plc as Director on Thursday 23 June 2016 and currently holding positions as Director Barbara Gayle Duncan was appointed in over 2 companies and currently holding positions in over 1 Companies.













Adaptimmune Therapeutics Plc



Address


                                    101 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY
                                



Standard Industry Classification (SIC)


                                    Research and experimental development on biotechnology (72110)
                                


Company Status

active




Appointment


ACTIVE
                                    Thursday 23 June 2016
                                    
                                


Association
Barbara Gayle Duncan is associated with Adaptimmune Therapeutics Plc since Thursday 23 June 2016 as Director


View Full Profile of Adaptimmune Therapeutics Plc >









Intercept Pharma Europe Limited



Address


                                    One, Glass Wharf, Bristol, , BS2 0ZX
                                



Standard Industry Classification (SIC)


                                    Wholesale of pharmaceutical goods (46460)
                                


Company Status

active




Appointment


RESIGNED
                                    Thursday 18 September 2014 to Wednesday 28 September 2016
                                    
                                


Association
Barbara Gayle Duncan is associated with Intercept Pharma Europe Limited since Thursday 18 September 2014 as Director


View Full Profile of Intercept Pharma Europe Limited >





Barbara Gayle Duncan - Latest News


Barbara Gayle Duncan MBA, CPA4 Traders • Wednesday 12 July 2017Ms. Barbara G. Duncan is on the Board of Directors at Ovid Therapeutics, Inc., ObsEva SA, Innoviva, Inc., Adaptimmune Therapeutics Plc, Adaptimmune Ltd., Jounce Therapeutics, Inc., Aevi Genomic Medicine, Inc. and Edgemont Pharmaceuticals LLC. Ms. Duncan ...
Aevi Genomic Medicine Inc.Market Watch • Friday 07 July 2017Dr. Garry A. Neil, MD, is Chief Scientific Officer at Medgenics, Inc., a Member at BioMarker Pharmaceuticals, Inc., a Principal at American College of Gastroenterology, and a Principal at The FDA Alliance. He is on the Board of Directors at J.&J. Denholm ...
ADAPTIMMUNE THERAPEUTICS PLCbeta.companieshouse.gov.uk • Thursday 29 June 201723 Dec 2015 AA01 Current accounting period shortened from 30 June 2016 to 31 December 2015 View PDF ( Current accounting period shortened from 30 June 2016 to 31 December 2015 - link opens in a new window ) (1 page) 23 Dec 2015 CH01 Director's details ...
Analyst Activity  Wedbush Reiterates Outperform on Intercept Pharmaceuticals (NASDAQ:ICPT)marketexclusive.com • Saturday 31 December 2016Today, Wedbush reiterated its Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of $224.00. There are 4 sell ratings, 3 hold ratings, 11 buy ratings on the stock. The current consensus rating on Intercept Pharmaceuticals ...


View All News Articles >






Site2Corp - United Kingdom (UK)
Company Search
Director Search
Company By Zip Code
Insights
Company Statistics

Help
Frequently Asked Questions
Contact Us
Terms and Conditions
Privacy Policy

Looking for Companies In ?


India (IN)
United Kingdom (UK)




Copyright © 2016 Site2Corp











Barbara Gayle Duncan - Former Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc.



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





Barbara Gayle Duncan
Former Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc.



Overview
In The News Relationships Paths
Education Career History Boards & Committees Public Holdings Transactions Awards & Honors 


Barbara Gayle Duncan
Former Chief Financial Officer, Secretary & Treasurer at Intercept Pharmaceuticals, Inc.



 Overview



Age



52
                                  (Born 1965)
                                              




Notable Companies


Intercept Pharmaceuticals, Inc.

DOV Pharmaceutical, Inc.




Awards



1





Board Seats



10





Number of Relationships



                This person is connected to 1,472 people.
              






 In The News
          See more




RelSci
June 15, 2017





                        Barbara Gayle Duncan is now serving in a new board position at Ovid Therapeutics, Inc.                    





GlobeNewswire
June 14, 2017





                        Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors                    





PR Newswire
April 26, 2017





                        Sarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Cut Costs                    





Business Wire
April 20, 2017





                        Innoviva Announces Preliminary Results of Annual Meeting                    





GlobeNewswire
March 10, 2017





                        Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results                    







See full news coverage and complete stories with RelSci Professional.

Create Your News Feed








See  More 






 Relationships
              See Details




James J. Noble

Chief Executive Officer & Executive Director at Adaptimmune Therapeutics PLC




Douglas A. Saltel

Founder at Edgemont Pharmaceuticals LLC





Michael F. Cola

Director, President & Chief Executive Officer at Aevi Genomic Medicine, Inc.




Ernest Loumaye

Co-Founder at ObsEva SA





Matthew J. During

Founder at Ovid Therapeutics, Inc.




Eugene A. Bauer

Founder & Chief Medical Officer at Dermira, Inc.





Jeremy M. Levin

Chief Executive Officer & Chairman of the Board at Ovid Therapeutics, Inc.




David Mott

General Partner & Head, Healthcare Investing Practice at New Enterprise Associates LLC





Elliott Sigal

Venture Partner & Senior Advisor, Washington DC at New Enterprise Associates LLC




Richard Murray

Chief Executive Officer & President at Jounce Therapeutics, Inc.







See 1,462 more listings with RelSci Professional.

Start My Free Trial ➤








See 1,462 More 


 


 Paths to Barbara Gayle Duncan



            Barbara Gayle Duncan          




 You



 Connections via Relationship Science



 Barbara Gayle Duncan






Sync your contacts to see how you can connect with Barbara Gayle Duncan.

Start My Free Trial ➤








See  More 


 


 Educational Background



M.B.A. 
Class of 1994 


University of Pennsylvania - The Wharton School

                  The Wharton School is the business school of the University of Pennsylvania, an Ivy League university in Philadelphia, Pennsylvania. Wharton was the world’s first collegiate business school and the first business school in the United States. It was established in 1881 through a donation of Joseph Wharton.                




BS Accounting 
Class of 1985 


Louisiana State University

                  Louisiana State University and Agricultural and Mechanical College (most often referred to as Louisiana State University or LSU) is a public coeducational university located in Baton Rouge, Louisiana.[7] The University was founded in 1853 in what is now known as Pineville, Louisiana, under the name Louisiana State Seminary of Learning & Military Academy. The current LSU main campus was dedicated in 1926, and consists of more than 250 buildings constructed in the style of Italian Renaissance architect Andrea Palladio, and occupies a 650-acre (2.6 km²) plateau on the banks of the Mississippi River.                





 Career History



Chief Financial Officer, Secretary & Treasurer

                                    2009 - 2016                


Intercept Pharmaceuticals, Inc.


                  Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.                




Chief Executive & Financial Officer

                                    2001 - 2009                


DOV Pharmaceutical, Inc.


                  DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ.                




Vice President-Corporate Finance Division

                                    1998 - 2001                


Lehman Brothers, Inc.


                  Lehman Brothers, Inc. was a broker/dealer headquartered in New York City. They provided global equity and fixed research. The equity research department covered more than 100 sectors. They used a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman had also developed special products, such as 10 uncommon values and 10 uncommon eurovalues.                




Director & Associate

                                    1994 - 1998                


SBC Warburg Dillon Read Corporate Finance AG






Associate

                                    1994 - 1998                


SBC Warburg






Auditor

                                    1989 - 1992                


PepsiCo, Inc.


                  PepsiCo, Inc. engages in the manufacturing, marketing, distribution, and sale of beverages, foods, and snacks. It is a food and beverage company with a complementary portfolio of brands, including Frito-Lay, Gatorade, Pepsi-Cola, Quaker and Tropicana. It operates through the following segments: Frito-Lay North America; Quaker Foods North America; North America Beverages; Latin America; Europe Sub-Saharan Africa; and Asia, Middle East, and North Africa. The Frito-Lay North America segment markets, distributes, and sells snack foods under the Lay's, Doritos, Cheetos, Tostitos, Fritos, Ruffles, and Santitas brands. The Quaker Foods North America segment includes cereals, rice, and pasta under the Quaker, Aunt Jemima, Quaker Chewy, Cap'n Crunch, Life, and Rice-A-Roni brands. The North America Beverages segment consists of beverage concentrates, fountain syrups, and finished goods under various beverage brands such as Pepsi, Gatorade, Mountain Dew, Diet Pepsi, Aquafina, Diet Mountain Dew, Tropicana Pure Premium, Sierra Mist, and Mug. The Latin America segment covers beverage, food, and snack businesses in Latin America region. The Europe Sub-Saharan Africa segment comprises of beverage, food, and snack goods in Europe and Sub-Saharan Africa regions. The Asia, Middle East, and North Africa segment offers snack food products under the Lay's, Kurkure, Chipsy, Doritos, Cheetos, and Crunchy brands. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.                




Auditor

                                    1986 - 1989                


Deloitte & Touche LLP


                  Deloitte & Touche LLP offers auditing and consulting services. It also provides accounting, financial advisory, risk management, and tax services. The company engages in international financial reporting, assurance, advisory, tax auditing, corporate governance, risk consulting, advisory services, mergers and acquisitions, government compliance, and human capital consulting services. The company was founded on May 6, 1997 and is headquartered in New York, NY.                




Public Accountant

                                    1986 - 1989                


Deloitte LLP


                  Deloitte LLP provides audit, consulting, financial advisory, risk management, tax, and related services. It offers financial transaction, regulatory, forensic and compliance, resilience and merger and acquisition services. The company was founded on March 7, 1995 and is headquartered in New York, NY.                





 Boards & Committees



Corporate Boards ▾




Member, Board of Directors

                    2017 - Current                  


Ovid Therapeutics, Inc.

                    Ovid Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing impactful medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.                  




Member, Board of Directors

                    2016 - Current                  


Innoviva, Inc.

                    Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.
Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.                  




Independent Director

                    2016 - Current                  


Adaptimmune Therapeutics PLC

                    Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.                  




Non-Executive Director

                    2016 - Current                  


Adaptimmune Ltd.

                    Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.                  




Member, Board of Directors

                    2016 - Current                  


Jounce Therapeutics, Inc.

                    Jounce Therapeutics, Inc. develops and manufactures drugs and immunotherapies. It produces cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharmain in 2013 and is headquartered in Cambridge, MA.                  




Independent Director

                    2016 - Current                  


ObsEva SA

                    ObsEva SA provides therapeutic treatments to increase women's reproductivity. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.                  




Director

                    2010 - Current                  


Edgemont Pharmaceuticals LLC

                    Edgemont Pharmaceuticals LLC develops and provides products for psychiatric disorders. The company was founded by Douglas A. Saltel in 2008 and is headquartered in Austin, TX.                  




Director & Associate

                    1994 - 1998                  


SBC Warburg Dillon Read Corporate Finance AG






Director

                    Prior                  


SBC Warburg






Director

                    2015 - ?                  


Aevi Genomic Medicine, Inc.

                    Aevi Genomic Medicine, Inc. is a medical technology company, which focuses on finding treatments for rare and orphan diseases, with a particular focus on pediatrics, following a genomics medicine strategy. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.                  





 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Transactions



 Details Hidden



                  Intercept Pharmaceuticals, Inc. issued Common Stock                                  




 Details Hidden



                  Intercept Pharmaceuticals, Inc. raised money in a private placement transaction                                  





 Awards & Honors




                  Professional Certification                




CPA (Certified Public Accountant)

                                    Sponsored by
                  American Institute of Certified Public Accountants






 Other Affiliations




              Barbara Gayle Duncan is affiliated with
                            Intercept Pharmaceuticals, Inc., DOV Pharmaceutical, Inc., Lehman Brothers, Inc., SBC Warburg Dillon Read Corporate Finance AG, SBC Warburg, PepsiCo, Inc., Deloitte & Touche LLP, Deloitte LLP, Ovid Therapeutics, Inc., Innoviva, Inc., Adaptimmune Therapeutics PLC, Adaptimmune Ltd., Jounce Therapeutics, Inc., ObsEva SA, Edgemont Pharmaceuticals LLC, SBC Warburg Dillon Read Corporate Finance AG, SBC Warburg, Aevi Genomic Medicine, Inc..
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤















Barbara Gayle  Duncan - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Barbara Gayle  Duncan
Check out list of companies and businesses related to Barbara Gayle  Duncan. Find out Barbara Gayle  Duncan address and contact details. View other people related to Barbara Gayle  Duncan - coworkers, colleagues, companions, etc.
Address:   

C/O DOV PHARMACEUTICAL, INC. 150 PIERCE STREET SOMERSET 08873 NJ




Companies related to Barbara Gayle  Duncan
CIKCompany NamePositionCompany Address0001066833Euthymics Bioscience, Inc.Director 35 BRAINTREE HILL OFFICE PARK SUITE 304 BRAINTREE 021840001080014Innoviva, Inc.Director 2000 SIERRA POINT PARKWAY SUITE 500 BRISBANE 940050001138776Aevi Genomic Medicine, Inc.Director 435 DEVON PARK DRIVE, SUITE 715 WAYNE 190870001270073INTERCEPT PHARMACEUTICALS INCChief Accounting Officer 450 W. 15TH STREET SUITE 505 NEW YORK 100110001621227Adaptimmune Therapeutics PLCDirector 101 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE OX14 4RY0001636651Ovid Therapeutics Inc.Director 1460 BROADWAY SUITE 15044 NEW YORK 100360001640455Jounce Therapeutics, Inc.780 MEMORIAL DRIVE  CAMBRIDGE 02139




Barbara Gayle  Duncan on the Web
Persons related to Barbara Gayle  Duncan - Euthymics Bioscience, Inc.NamePositionCitySokol  AlbertBostonE. Jackson  AlexanderLONDON SW3 4LY UNITED KINGDOME. Jackson  AlexanderNEW YORKBaker  AndrewMelbourne VICMcKinney  AnthonyBraintreeMcKinney  AnthonyCambridgeMcKinney  AnthonyCambridgePatrick  AsheDirector HACKENSACKPatrick  AsheDirector SOMERSETPatrick  AsheDirector SOMERSETSmith  BrigitteMelbourneMurray  CampbellCambridgeMurray  CampbellCambridgeIMPERIAL BANK OF COMMERCE /CAN/  CANADIANOmstead  DanielBostonBranch  DouglasOklahoma CityDOV PHARMACEUTICAL INCDirector HACKENSACKDOV PHARMACEUTICAL INCSVP & CSO HACKENSACKDOV PHARMACEUTICAL INCDirector HACKENSACKDOV PHARMACEUTICAL INCSenior V.P. & General Counsel HACKENSACKDOV PHARMACEUTICAL INCDirector SOMERSETDOV PHARMACEUTICAL INCDirector SOMERSETGlenn  DubinNEW YORKBarbara Gayle  DuncanDirector SOMERSETELAN CORP PLC10% Owner DUBLIN 2ELAN INTERNATIONAL SERVICES LTDBERMUDAELAN PHARMACEUTICAL INVESTMENTS LTDELAN PHARMACEUTICAL INVESTMENTS LTDELAN PHARMACEUTICAL INVESTMENTS LTDSMITHS FL 04Gentile  FrankBostonBymaster  FranklinBrownsburgHIGHBRIDGE CAPITAL MANAGEMENT LLC10% Owner NEW YORKHighbridge International LLCGEORGE TOWN, CAYMAN ISLANDSZOLA P  HOROVITZDirector HACKENSACKZOLA P  HOROVITZDirector SOMERSETZOLA P  HOROVITZDirector PLYMOUTH MEETINGLeslie  HudsonCEO and President HACKENSACKSAMUEL D  ISALYNEW YORKBailey  JeffreyWolfeboroJoshua  FunderMelbourne VICArnold  LippaDirector SOMERSETScott Dunseth  MyersSenior Vice President HACKENSACKScott Dunseth  MyersSenior Vice President SOMERSETORBIMED ADVISORS LLCORBIMED ADVISORS LLCDirector NEW YORKORBIMED CAPITAL LLCORBIMED CAPITAL LLCNEW YORKG. G. Dear  PatrickLONDON SW3 4LY UNITED KINGDOMG. G. Dear  PatrickLONDONWeiss  PaulMadisonWeiss  PaulMadisonTran  PierreCambridgeDennis  PodlesakDirector HACKENSACKDennis  PodlesakDirector SOMERSETDennis  PodlesakSOMERSETPOLYGON GLOBAL OPPORTUNITIES MASTER FUNDLONDON SW3 4LY UNITED KINGDOMPOLYGON GLOBAL OPPORTUNITIES MASTER FUND10% Owner LONDONPolygon Investment Management LTDLONDON SW3 4LY UNITED KINGDOMPolygon Investment Management LTDLONDONPolygon Investment Partners GP, LLCLONDON SW3 4LY UNITED KINGDOMPolygon Investment Partners GP, LLCNEW YORKPolygon Investment Partners HK LTDLONDON SW3 4LY UNITED KINGDOMPolygon Investment Partners HK LTDHONG KONGInvestment Partners LLP  PolygonLONDON SW3 4LY UNITED KINGDOMInvestment Partners LLP  PolygonLONDONPolygon Investment Partners LPLONDON SW3 4LY UNITED KINGDOMPolygon Investment Partners LPNEW YORKPolygon Investments Ltd.LONDON SW3 4LY UNITED KINGDOMPolygon Investments Ltd.GEORGE TOWN, GRAND CAYMANE. Griffith  ReadeLONDON SW3 4LY UNITED KINGDOME. Griffith  ReadeLONDONPhil  SkolnickSr. V.P. Research, CSO HACKENSACKPhil  SkolnickPresident and CSO SOMERSETWarren Charles  SternSr. V.P. Drug Development SOMERSETHenry  SwiecaNEW YORKShea  ThomasCambridgeBarberich  TimothyBostonBarberich  TimothyConcordAG  UBS RIPER DANIEL S  VANDirector HACKENSACKRIPER DANIEL S  VANDirector SOMERSETRIPER DANIEL S  VANSOMERSETPappafotopoulos  WilliamCambridgeJoseph S  ZakrzewskiSOMERSETJoseph S  ZakrzewskiDirector SOMERSETPersons related to Barbara Gayle  Duncan - Innoviva, Inc.NamePositionCityGEORGE B  ABERCROMBIESr. VP & Chief Comm. Officer DURHAMGEORGE B  ABERCROMBIESr. VP, Corp. Partnerships SOUTH SAN FRANCISCOMichael W  AguiarPresident & Chief Exec Officer SOUTH SAN FRANCISCOMichael W  AguiarSr VP, Chief Financial Officer SOUTH SAN FRANCISCOMichael W  AguiarPresident & CEO SOUTH SAN FRANCISCOJULIAN  BAKERNEW YORKJULIAN  BAKERDirector NEW YORKJULIAN  BAKERDirector NEW YORKLEONARD M  BLUMSr VP, Chief Comm. Officer SOUTH SAN FRANCISCOLEONARD M  BLUMSr VP, Chief Comm. Officer SOUTH SAN FRANCISCODavid L  BrinkleyHead of Business Dev. SOUTH SAN FRANCISCOArthur L  CampbellSr. VP, Technical Operations SOUTH SAN FRANCISCOEric  dEsparbesSVP and CFO SOUTH SAN FRANCISCOEric  dEsparbesSVP and CFO SOUTH SAN FRANCISCOJEFFREY M  DRAZANDirector MENLO PARKJEFFREY M  DRAZANDirector MENLO PARKJEFFREY M  DRAZANDirector MENLO PARKJEFFREY M  DRAZANDirector SAN MATEOJEFFREY M  DRAZANMENLO PARKBarbara Gayle  DuncanDirector SOMERSETMichael E.  FaermSr VP & Chief Business Officer SOUTH SAN FRANCISCOHenrietta  ForeDirector SOUTH SAN FRANCISCOCATHY  FRIEDMANDirector SANTA CLARACATHY  FRIEDMANDirector SOUTH SAN FRANCISCOCATHY  FRIEDMANDirector SOUTH SAN FRANCISCOPLC  GLAXOSMITHKLINE10% Owner BRENTFORD MIDDLESEXPLC  GLAXOSMITHKLINE10% Owner BRENTFORD MIDDLESEX,MARTY  GLICKExecutive VP, Finance and CFO SOUTH SAN FRANCISCORobert V  Gunderson JRDirector MENLO PARKRobert V  Gunderson JRDirector REDWOOD CITYPatrick PA  HumphreyExecutive VP Research SOUTH SAN FRANCISCOJEFFREY DAVID  JONKERSenior VP, Corp. & Bus. Dev. SOUTH SAN FRANCISCOTerrence C  KearneyDirector LAKE FORESTTerrence C  KearneyDirector SOUTH SAN FRANCISCOMichael  KittSr. Vice President Development SOUTH SAN FRANCISCOJUNNING  LEESr. VP, Technical Operations SOUTH SAN FRANCISCOJUNNING  LEESr. VP, Technical Operations SOUTH SAN FRANCISCOPATRICK G  LEPOREDirector FAIR LAWNARNOLD J  LEVINEDirector CARVERSVILLEARNOLD J  LEVINEDirector CARVERSVILLEARNOLD J  LEVINEDirector SOUTH SAN FRANCISCORonn  LoewenthalDirector SAN FRANCISCOBURTON G  MALKIELDirector SOUTH SAN FRANCISCOMathai  MammenSVP, Research & Early Clin Dev SOUTH SAN FRANCISCOMathai  MammenSVP, Research & Early Clin Dev SOUTH SAN FRANCISCOMICHAEL  MULLENSOUTH SAN FRANCISCOFRANK  PASQUALONESr. Vice President, Operations SOUTH SAN FRANCISCOPAUL  PEPEDirector SOUTH SAN FRANCISCOPETER S  RINGROSEDirector SOUTH SAN FRANCISCOBradford J  ShaferSr VP, Gen. Counsel, Secretary SOUTH SAN FRANCISCOBradford J  ShaferSOUTH SAN FRANCISCOBradford J  ShaferSr VP, Gen. Counsel, Secretary SOUTH SAN FRANCISCOEve Elizabeth  SlaterDirector SHORT HILLSEve Elizabeth  SlaterDirector SOUTH SAN FRANCISCOA Gregory  SturmerVice President Finance SOUTH SAN FRANCISCOJames L  TyreeDirector ABBOTT PARKJames L  TyreeDirector SOUTH SAN FRANCISCOJames L  TyreeDirector SOUTH SAN FRANCISCOP ROY  VAGELOSDirector SOUTH SAN FRANCISCOWILLIAM H  WALTRIPDirector ROCHESTERWILLIAM H  WALTRIPDirector SOUTH SAN FRANCISCOWILLIAM H  WALTRIPDirector SOUTH SAN FRANCISCOGEORGE M  WHITESIDESDirector CAMBRIDGEGEORGE M  WHITESIDESDirector SOUTH SAN FRANCISCORick E  WinninghamChief Executive Officer SOUTH SAN FRANCISCORick E  WinninghamDirector SOUTH SAN FRANCISCOTHEODORE L  WITEK JRSr. VP & Chief Scientific Off. SOUTH SAN FRANCISCOWILLIAM D  YOUNGDirector SOUTH SAN FRANCISCOWILLIAM D  YOUNGDirector SOUTH SAN FRANCISCOPersons related to Barbara Gayle  Duncan - Aevi Genomic Medicine, Inc.NamePositionCityClemow  AlastairPrincetonClemow  AlastairWayneClemow, PhD  AlastairSan FranciscoPearlman  AndrewMisgavPearlman  AndrewMisgavPearlman, PhD  AndrewSan FranciscoScott  ApplebaumChief Legal Officer WAYNEDuncan  BarbaraWayneSOL J  BARERDirector WARRENSOL J  BARERDirector SAN FRANCISCOSOL J  BARERDirector WAYNEStern  BaruchMisgavStern  BaruchMisgavEUGENE A  BAUERDirector PALO ALTOEUGENE A  BAUERDirector SAN FRANCISCOEUGENE A  BAUERDirector WAYNEEUGENE A  BAUERVIENNAPhyllis K.  BellinVIENNAPhyllis K.  BellinSee Remarks SAN FRANCISCOPhyllis K.  BellinSee Remarks SAN FRANCISCOPhyllis K.  BellinSee Remarks WAYNEStephen  BellomoVIENNAStephen  BellomoSee Remarks SAN FRANCISCOISAAC  BLECHDirector NEW YORKISAAC  BLECHDirector NEW YORKGARY A  BRUKARDTDirector VIENNAGARY A  BRUKARDTDirector SAN FRANCISCOCHICAGO INVESTMENTS INCVIENNA,CHICAGO INVESTMENTS INC10% Owner VIENNADellio  ClarenceSan FranciscoALASTAIR J  CLEMOWDirector WAYNEALASTAIR J T  CLEMOWDirector PRINCETONALASTAIR J T  CLEMOWVIENNAALASTAIR J T  CLEMOWDirector SAN FRANCISCOALASTAIR J T  CLEMOWDirector SAN FRANCISCOALASTAIR J T  CLEMOWDirector WAYNEMICHAEL F  COLAPresident and CEO WAYNEMICHAEL F  COLAPresident and CEO WAYNEMICHAEL F  COLAPresident and CEO WAYNECLARENCE L  DELLIOSAN FRANCISCOCLARENCE L  DELLIOChief Operating Officer SAN FRANCISCOCLARENCE L  DELLIOChief Operating Officer SAN FRANCISCOCLARENCE L  DELLIOChief Operating Officer WAYNEBarbara Gayle  DuncanDirector SOMERSETShoshani  EhudMisgavof Lord Leonard Steinberg  Estate10% Owner HALEBARNS CHESHIREBauer  EugeneEmeryvilleBauer  EugeneWayneBauer, MD  EugeneSan FranciscoWILBUR H  GANTZDirector WILBUR H  GANTZDirector LAKE FORESTWILBUR H  GANTZDirector WAYNEMarvin  GarovoyChief Medical Officer SAN FRANCISCONeil  GarryWayneBrukardt  GaryNashvilleBrukardt  GaryNashvilleBrukardt  GarySan FranciscoJOSEPH J  GRANO JRDirector NEW YORK CITYJOSEPH J  GRANO JRDirector WAYNEPHILIP R  HARPER10% Owner BETHESDABlech  IsaacWayneBlech  IsaacSan FranciscoKanter  JoelViennaKanter  JoelSan FranciscoLeaman  JohnWayneGrano Jr.  JosephWayneJOEL S  KANTERDirector SAN FRANCISCOJOEL S  KANTERDirector SAN FRANCISCOJOEL S  KANTERDirector WAYNEJOEL S  KANTERVIENNAJoshua  KanterSALT LAKE CITY,Joshua  Kanter10% Owner SALT LAKE CITYJohn Harold  LeamanChief Financial Officer SAN FRANCISCOJohn Harold  LeamanChief Financial Officer WAYNESteinberg  LeonardLiverpoolLiberty Charitable Remainder Trust f/b/o Isaac BlechNEW YORKSTEPHEN D  MCMURRAYDirector VIENNASTEPHEN D  MCMURRAYVIENNASTEPHEN D  MCMURRAYDirector SAN FRANCISCOSTEPHEN D  MCMURRAYDirector SAN FRANCISCOSTEPHEN D  MCMURRAYDirector WAYNECola  MichaelWayneGARRY ARTHUR  NEILChief Scientific Officer SAN FRANCISCOGARRY ARTHUR  NEILChief Scientific Officer WAYNEAndrew  PearlmanVIENNAAndrew  PearlmanPresident and CEO SAN FRANCISCOAndrew  PearlmanPresident and CEO SAN FRANCISCOAndrew  PearlmanPresident and CEO SAN FRANCISCOAndrew  PearlmanDirector WAYNEBellin  PhyllisMisgavBellin  PhyllisMisgavBellin  PhyllisSan FranciscoBrian  PiperChief Financial Officer WAYNECharitable Remainder Unitrust f/b/o Isaac Blech  RiverNEW YORKCharitable Remainder Unitrust f/b/o Isaac Blech  RiverNEW YORKApplebaum  ScottWayneBarer  SolWayneBellomo  StephenMisgavBellomo  StephenMisgavBellomo  StephenSan FranciscoMcMurray  StephenFt. WayneMcMurray, MD  StephenSan FranciscoBaruch  SternVIENNABaruch  SternChief Scientific Officer VIENNACharitable Remainder Unitrust  WestNEW YORKGantz  Wilbur IIIWaynePersons related to Barbara Gayle  Duncan - INTERCEPT PHARMACEUTICALS INCNamePositionCityLuciano  AdoriniChief Scientific Officer NEW YORKLuciano  AdoriniChief Scientific Officer NEW YORKLuciano  AdoriniChief Scientific Officer NEW YORKSRINIVAS  AKKARAJUDirector SRINIVAS  AKKARAJUDirector NEW YORKSRINIVAS  AKKARAJUDirector NEW YORKDuncan  BarbaraNew YorkLuca  BenattiDirector NEW YORKDANIEL  BRADBURYDirector SAN DIEGOLisa  BrightPresident International NEW YORKShapiro  DavidNew YorkBarbara Gayle  DuncanChief Accounting Officer SOMERSETBarbara Gayle  DuncanChief Financial Officer NEW YORKBarbara Gayle  DuncanChief Financial Officer NEW YORKBarbara Gayle  DuncanChief Financial Officer NEW YORKBarbara Gayle  DuncanChief Financial Officer NEW YORKJerome Benedict  DursoChief Operating Officer NEW YORKDavid A  FordChief Human Resources Officer NEW YORKPaolo  FundaroDirector NEW YORKPaolo  FundaroDirector NEW YORKS.p.A.  Genextra10% Owner MILANKeith Michael  GottesdienerDirector NEW YORKSAMUEL D  ISALYSAMUEL D  ISALYNEW YORKSAMUEL D  ISALYNEW YORKSilverstein  JonathanNew YorkSandip  KapadiaChief Financial Officer NEW YORKRichard J  KimSVP, Commercial US NEW YORKVeitinger  KlausNew YorkVeltinger  KlausNew YorkTallarigo  LorenzoNew YorkBenatti  LucaDirector NEW YORKAdorini  LucianoNew YorkPruzanski  MarkNew YorkRachel  McMinnChief Strategy Officer NEW YORKFrancesco  MicheliMILANFrancesco  Micheli10% Owner MILANFrancesco  Micheli10% Owner MILANWilliams  NicoleNew YorkORBIMED ADVISORS LLCDirector ORBIMED ADVISORS LLCDirector NEW YORKORBIMED ADVISORS LLCDirector NEW YORKOrbiMed Capital GP IV LLCNEW YORKOrbiMed Capital GP IV LLCNEW YORKOrbiMed Capital GP IV LLCNEW YORKPaolo  FundaroNew YorkSanj K  PatelNEW YORKSanj K  PatelDirector NEW YORKMark  PruzanskiCEO & President NEW YORKMark  PruzanskiPresident and CEO NEW YORKMark  PruzanskiPresident and CEO NEW YORKMark  PruzanskiCEO & President NEW YORKMark  PruzanskiCEO & President NEW YORKDaniel Paul  ReganChief Commerical Officer NEW YORKDaniel Paul  ReganChief Commercial Officer NEW YORKDaniel Paul  ReganChief Commercial Officer NEW YORKDaniel Paul  ReganChief Commercial Officer NEW YORKGINO  SANTINIDirector INDIANAPOLISGLENN  SBLENDORIODirector NEW YORKGLENN  SBLENDORIODirector NEW YORKGLENN  SBLENDORIONEW YORKDavid  ShapiroCMO and EVP - Development NEW YORKDavid  ShapiroCMO & EVP - Development NEW YORKDavid  ShapiroCMO and EVP - Development NEW YORKDavid  ShapiroCMO and EVP - Development NEW YORKDavid  ShapiroCMO and EVP - Development NEW YORKJONATHAN  SILVERSTEINDirector NEW YORKJONATHAN  SILVERSTEINDirector NEW YORKJONATHAN  SILVERSTEINDirector NEW YORKJONATHAN  SILVERSTEINDirector NEW YORKJONATHAN  SILVERSTEINDirector NEW YORKJONATHAN  SILVERSTEINDirector NEW YORKLORENZO  TALLARIGODirector NEW YORKLORENZO  TALLARIGODirector NEW YORKKLAUS R DR  VEITINGERDirector MIDDLETONKLAUS R DR  VEITINGERDirector NEW YORKKLAUS R DR  VEITINGERDirector NEW YORKKLAUS R DR  VEITINGERDirector NEW YORKDANIEL G  WELCHDirector BRISBANENICOLE  WILLIAMSDirector NICOLE  WILLIAMSDirector NEW YORKNICOLE  WILLIAMSDirector NEW YORKNICOLE  WILLIAMSDirector NEW YORKPersons related to Barbara Gayle  Duncan - Adaptimmune Therapeutics PLCNamePositionCityBehbahani  AliTimoniumLawrence M  AllevaDirector WALTHAMRafael  AmadoChief Medical Officer MALVERNM JAMES  BARRETT10% Owner BALTIMOREPETER J  BARRIS10% Owner BALTIMOREFOREST  BASKETT10% Owner BALTIMOREAli  BehbahaniDirector TIMONIUMWilliam C  Bertrand JRGAITHERSBURGGwendolyn Knowlton  Binder-SchollChief Technology Officer PHILADELPHIAMott  DavidTimoniumJonathan  Knowles  Dr.Abingdon, OxfordshireBarbara Gayle  DuncanDirector SOMERSETSigal  ElliottPrincetonAnthony A. Jr.  Florence10% Owner CHEVY CHASELaing  IanAbingdon, OxfordshireSAMUEL D  ISALYNoble  JamesAbingdon, OxfordshirePATRICK J  KERINS10% Owner BALTIMOREGiles Francis Bertram  KerrDirector OXFORDSHIREJonathan Kenneth Charles  KnowlesDirector BASELLANDKRISHNA KITTU  KOLLURIBALTIMOREIan Michael  LaingDirector OXFORDDAVID M  MOTTDirector GAITHERSBURGNEA 14 GP, LTDTIMONIUMNEA Partners 14, L.P.TIMONIUMNew Enterprise Associates 14, L.P.10% Owner TIMONIUMJames  NobleChief Executive Officer BRANFORDORBIMED ADVISORS LLCDirector OrbiMed Capital GP V LLCNEW YORKThompson  PeterNew YorkAdrian  RawcliffeChief Financial Officer BRENTFORD, MIDDLESEX, ENGLANDSCOTT D  SANDELL10% Owner BALTIMORECharles Elliott  SigalDirector PRINCETONPeter W.  Sonsini10% Owner MENLO PARKHelena Katrina  Tayton-MartinChief Operating Officer HUNGERFORDPeter A  ThompsonDirector BELLEVUERavi  Viswanathan10% Owner TIMONIUMHarry R  WellerBALTIMORETal Zvi  ZaksDirector NEWTONPersons related to Barbara Gayle  Duncan - Ovid Therapeutics Inc.NamePositionCityRakhit  AmitNew YorkFriedman  BartNew YorkKaren  BernsteinFORT WASHINGTONTimothy  DalyVP, Finance & Corp. Controller PISCATAWAYWilliams  DouglasNew YorkBarbara Gayle  DuncanDirector SOMERSETMatthew  DuringPresident and CSO NEW YORKBart  FriedmanHAMILTON, BERMUDA HM 12Dirk  HaasnerNEW YORKLevin  JeremyNew YorkLevin  JeremyNew YorkLevin  JeremyNew YorkBernstein  KarenNew YorkJEREMY M  LEVINCEO PRINCETONFeldberg  MarkNew YorkDuring  MatthewNew YorkDuring  MatthewNew YorkDuring  MatthewNew YorkAmit  RakhitNEW YORKYaron  WerberCBO, CFO, Sec. and Treas. NEW YORKDOUGLAS E  WILLIAMSBOTHELLWerber  YaronNew YorkWerber  YaronNew YorkPersons related to Barbara Gayle  Duncan - Jounce Therapeutics, Inc.NamePositionCityBarry  AnnaCambridgePfeffer  CaryCambridgeCELGENE CORP /DE/SUMMITCelgene Switzerland LLC10% Owner PEMBROKEKimberlee C  DrapkinLEXINGTONBarbara Gayle  DuncanSOMERSETHadley Harbor Master Investors (Cayman) L.P.10% Owner BOSTONJohn Duncan  HiggonsDirector CAMBRIDGERobert  KamenCAMBRIDGEPERRY A  KARSENDirector ROCKVILLEDrapkin  KimCambridgeMARK J  LEVINCAMBRIDGERICHARD /CA/  MURRAYFREMONTCary  PfefferCAMBRIDGEMurray  RichardCambridgeKamen  RobertCambridgeTepper  RobertCambridgeKEVIN P  STARRCAMBRIDGEROBERT I  TEPPERDirector CAMBRIDGEThird Rock Ventures GP II, L.P.BOSTONThird Rock Ventures GP III, L.P.BOSTONThird Rock Ventures II, L.P.10% Owner BOSTONThird Rock Ventures III, L.P.BOSTONElizabeth  TrehuCAMBRIDGETRV GP II, LLCBOSTONTRV GP III, LLCBOSTON












 











News on Barbara Gayle Duncan


























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology















                                Person                            


                                    Barbara Gayle Duncan                                    ▼





                                Topic                            


                                    All Topics                                    ▼








Organizations

                                Find news about organizations
                            





Alumni

                                Find news on alumni of any org
                            





Industries

                                Find news on a particular market
                            





Your Contacts

                                Find news on your contacts
                            








Sign up for free daily alerts on this feed:











By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


















Follow




                            Change Feed
                        


Barbara Gayle Duncan











Barbara Gayle Duncan is now serving in a new board position at Ovid Therapeutics, Inc.


                                June 15, 2017                                 • 
                                RelSci Data Update                            










Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors


                                June 14, 2017                                 • 
                                GlobeNewswire                            


                                  ... for patients with rare neurological disorders, today announced the appointment of Barbara G. Duncan to the company's board of directors, where she will serve as ...
                                









Sarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Cut Costs


                                April 26, 2017                                 • 
                                PR Newswire                            


                                  ... than that at Innoviva. We ask the Innoviva directors - Mike Aguiar, Barbara Duncan, Cathy Friedman, Patrick LePore, Paul Pepe, James Tyree and William Waltrip ...
                                









Innoviva Announces Preliminary Results of Annual Meeting


                                April 20, 2017                                 • 
                                Business Wire                            


                                  ... reelect all seven of Innoviva's director nominees-William H. Waltrip, Michael W. Aguiar, Barbara Duncan, Catherine J. Friedman, Patrick G. LePore, Paul Pepe and James L. ...
                                









Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results


                                March 10, 2017                                 • 
                                GlobeNewswire                            


                                  ... These additions follow several key appointments by Jounce in 2016 including Barbara G. Duncan and Perry A. Karsen to its Board of Directors, and Stephen ...
                                









Software Maker in Hot Momentum: Innoviva , salesforce.com 


                                March 9, 2017                                 • 
                                ICT Monitor Worldwide                            


                                  ... nominees, six of whom are independent: William H. Waltrip, Michael W. Aguiar, Barbara Duncan, Catherine J. Friedman, Patrick G. LePore, Paul Pepe and James L. ...
                                









Innoviva Files Preliminary Proxy Materials for 2017 Annual Meeting


                                March 7, 2017                                 • 
                                Business Wire                            


                                  ... nominees, six of whom are independent: William H. Waltrip, Michael W. Aguiar, Barbara Duncan, Catherine J. Friedman, Patrick G. LePore, Paul Pepe and James L. ...
                                









Innoviva Reports Fourth Quarter and Full Year 2016 Financial Results


                                February 9, 2017                                 • 
                                Business Wire                            


                                  ... million.Capital Returns:Expanded the Board of Innoviva by appointing Patrick G. LePore and Barbara Duncan as independent directors. Mr. LePore was formerly Chief Executive Officer and ...
                                









ObsEva Expands Leadership Team and Board of Directors with Industry Veterans


                                January 17, 2017                                 • 
                                GlobeNewswire                            


                                  ... serve as a non-executive Board member and Chair of Compensation Committee. Additionally, Barbara Duncan, formerly of Intercept Pharmaceuticals, Inc., has joined ObsEva's Board of Directors ...
                                









Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer


                                June 9, 2016                                 • 
                                GlobeNewswire                            


                                  ... appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since ...
                                









Adaptimmune Strengthens Board with Appointment of Barbara Duncan


                                May 24, 2016                                 • 
                                GlobeNewswire                            


                                  ... leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective ...
                                









On the Boards


                                June 22, 2015                                 • 
                                Philadelphia Inquirer                            


                                  ... a Philadelphia medical-technology company that develops protein therapeutics medical therapies, has named Barbara Duncan to its board, effective July 22. Duncan serves as chief financial ...
                                









Barbara Gayle Duncan sold $1.28M worth of shares in Intercept Pharmaceuticals, Inc. in January 2014


                                February 8, 2014                                 • 
                                RelSci Data Update                            










Intercept Announces Pricing of Public Offering of Common Stock By Selling Stockholders


                                October 8, 2013                                 • 
                                PR Newswire                            


                                  ... candidate to Dainippon Sumitomo Pharma. For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000. SOURCE Intercept ...
                                









Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting


                                October 1, 2013                                 • 
                                PR Newswire                            


                                  ... information unless required by law. For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals, at 1-646-747-1000. SOURCE Intercept ...
                                









Intercept Pharmaceuticals to Present at the JMP Securities Healthcare Conference


                                July 1, 2013                                 • 
                                PR Newswire                            










Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock


                                June 18, 2013                                 • 
                                PR Newswire                            


                                  ... Pharma. For more information about Intercept, please contact Mark Pruzanski, MD, or Barbara Duncan, both of Intercept Pharmaceuticals at 1-646-747-1000. SOURCE Intercept Pharmaceuticals ...
                                









Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock


                                June 17, 2013                                 • 
                                PR Newswire                            


                                  ... law. For more information about Intercept, please contact Mark Pruzanski, MD, or Barbara Duncan, both of Intercept Pharmaceuticals at 1-646-747-1000. SOURCE Intercept Pharmaceuticals ...
                                









VC Community is Gearing up for BIO-Europe Spring® 2013


                                February 20, 2013                                 • 
                                Business Wire                            








Related News Feeds






Intercept Pharmaceuticals, Inc.







Pharmaceuticals







Board and Executive Moves in Pharmaceuticals







Alumni of University of Pennsylvania - The Wharton School

























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink



 






Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!


Start My Free Trial  ➤










 Industry:




 Select a Topic:



 Keyword:



Go  ➤









 Find an Organization:






 Select a Topic:




 Keyword:




Go  ➤









 Find a Person:






 Select a Topic:




 Keyword:




Go  ➤









 Name of a School:







 Or Name of an Organization:









 Select a Topic:




 Keyword:




Go  ➤








Thank you. You are now subscribed.Please wait for the page to refresh...










You are now subscribed to this feed.










You have unsubscribed to this feed.










Thank you. You can now subscribe to more RelSci news feeds.










 To subscribe to more than one feed, please enter a password.




 Please confirm your password



Go  ➤








You've found a premium RelSci Pro feature!



Follow News On Your Contacts

Upgrade to RelSci Pro now to easily sync your contacts and stay in the know on the news about the people important to you.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now








You've found a premium RelSci Pro feature!



Search News On Keywords

Curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now













Industries

                        Find news on a particular market
                    





People

                        Find news about people
                    





Organizations

                        Find news about organizations
                    





Alumni

                        Find news on alumni of any org
                    





Your Contacts

                        Find news on your contacts
                    












                Free Daily Alerts
            


                Sign up for free daily alerts on this feed
            




Sign Up ➤

                    By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions




                Already have an account?  Click here to login.















Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤
















Duncan Barbara Gayle Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      Duncan Barbara Gayle
                    

•   NEW YORK, NY
                      
How do I update this listing?




                                             Duncan Barbara Gayle is based out of New York.    WhaleWisdom has at least 6 insider transactions (Form 3,4,5) in our database for Duncan Barbara Gayle. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from Duncan Barbara Gayle, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




duncan barbara gayle


C/O INTERCEPT PHARMACEUTICALS, INC.

NEW YORK
NY
                                                        
                                                    10013


                                                      Business Phone:
                                                      646-747-1000
SEC SIC CODE:2834-PHARMACEUTICAL PREPARATIONS







Recent SEC Filings




4 filed on 07/03/2017
4 filed on 06/15/2017
3 filed on 06/15/2017
4 filed on 04/24/2017
3 filed on 01/26/2017
4 filed on 11/21/2016
3 filed on 11/21/2016
4 filed on 10/05/2016
4 filed on 07/07/2016
3 filed on 06/23/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















